DK1750703T3 - Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur - Google Patents
Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafurInfo
- Publication number
- DK1750703T3 DK1750703T3 DK05738545.2T DK05738545T DK1750703T3 DK 1750703 T3 DK1750703 T3 DK 1750703T3 DK 05738545 T DK05738545 T DK 05738545T DK 1750703 T3 DK1750703 T3 DK 1750703T3
- Authority
- DK
- Denmark
- Prior art keywords
- tegafur
- administration
- gastrointestinal toxicity
- toxicity caused
- reducing gastrointestinal
- Prior art date
Links
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title abstract 3
- 229960001674 tegafur Drugs 0.000 title abstract 3
- 206010059024 Gastrointestinal toxicity Diseases 0.000 title abstract 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 title abstract 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 235000020937 fasting conditions Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229950000193 oteracil Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56618004P | 2004-04-29 | 2004-04-29 | |
| PCT/JP2005/008450 WO2005105086A1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1750703T3 true DK1750703T3 (da) | 2012-05-07 |
Family
ID=35241420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05738545.2T DK1750703T3 (da) | 2004-04-29 | 2005-04-27 | Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080166427A1 (enExample) |
| EP (1) | EP1750703B1 (enExample) |
| JP (1) | JP5376758B2 (enExample) |
| AT (1) | ATE540679T1 (enExample) |
| AU (1) | AU2005237364B2 (enExample) |
| CY (2) | CY1112451T1 (enExample) |
| DK (1) | DK1750703T3 (enExample) |
| ES (1) | ES2378072T3 (enExample) |
| HR (1) | HRP20120293T1 (enExample) |
| ME (1) | ME01335B (enExample) |
| PL (1) | PL1750703T3 (enExample) |
| PT (1) | PT1750703E (enExample) |
| RS (1) | RS52217B (enExample) |
| RU (1) | RU2348409C2 (enExample) |
| SI (1) | SI1750703T1 (enExample) |
| WO (1) | WO2005105086A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201039816A (en) * | 2009-05-13 | 2010-11-16 | Taiho Pharmaceutical Co Ltd | Treatment of diffuse-type gastric cancers using S-1 and cisplatin |
| JP5863047B2 (ja) * | 2009-07-17 | 2016-02-16 | ミリアド ジェネティクス， インコーポレイテッド | ５−ｆｕをアッセイする方法 |
| WO2011022174A1 (en) * | 2009-08-21 | 2011-02-24 | Myriad Genetics, Inc. | Method of processing blood samples containing 5-fu |
| EP2422815A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours |
| EP2422784A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422848A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| CN106456631A (zh) * | 2014-03-06 | 2017-02-22 | 南加利福尼亚大学 | 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用 |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| US10117872B2 (en) * | 2014-03-28 | 2018-11-06 | Università Degli Studi Di Genova | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| WO2016175324A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| JP6439761B2 (ja) * | 2016-08-09 | 2018-12-19 | トヨタ自動車株式会社 | ＮＯｘ吸蔵還元触媒の製造方法 |
| CN106619689B (zh) * | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| US20250186435A1 (en) * | 2020-05-19 | 2025-06-12 | Cellix Bio Private Limited | Pharmaceutical formulations and their preparations for treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635946A (en) * | 1969-07-22 | 1972-01-18 | Solomon Aronovich Giller | N1-(2'-furanidyl)-derivatives of 5-substituted uracils |
| DE3585869D1 (de) * | 1984-10-30 | 1992-05-21 | Otsuka Pharma Co Ltd | Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung. |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| DE69003670T2 (de) * | 1989-01-05 | 1994-01-27 | Otsuka Pharma Co Ltd | Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs. |
| AU654555B2 (en) * | 1991-05-27 | 1994-11-10 | Taiho Pharmaceutical Co., Ltd. | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| WO2000021956A1 (en) * | 1998-10-12 | 2000-04-20 | Leonidov Nikolai B | New crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl)-uracyl, and complex compounds based on this modification and having an antitumoral activity |
-
2005
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en not_active Expired - Lifetime
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es not_active Expired - Lifetime
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
- 2005-04-27 RS RS20120127A patent/RS52217B/sr unknown
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en not_active Ceased
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
-
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I2/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005237364B2 (en) | 2010-07-08 |
| EP1750703A1 (en) | 2007-02-14 |
| EP1750703B1 (en) | 2012-01-11 |
| ME01335B (me) | 2013-12-20 |
| US20080166427A1 (en) | 2008-07-10 |
| CY2012014I1 (el) | 2016-04-13 |
| RU2348409C2 (ru) | 2009-03-10 |
| SI1750703T1 (sl) | 2012-02-29 |
| ES2378072T3 (es) | 2012-04-04 |
| PT1750703E (pt) | 2012-02-23 |
| EP1750703A4 (en) | 2008-02-27 |
| HRP20120293T1 (hr) | 2012-04-30 |
| RU2006142101A (ru) | 2008-06-20 |
| CY2012014I2 (el) | 2016-04-13 |
| AU2005237364A1 (en) | 2005-11-10 |
| RS52217B (sr) | 2012-10-31 |
| WO2005105086A1 (en) | 2005-11-10 |
| PL1750703T3 (pl) | 2012-05-31 |
| JP5376758B2 (ja) | 2013-12-25 |
| ATE540679T1 (de) | 2012-01-15 |
| CY1112451T1 (el) | 2015-12-09 |
| JP2007534634A (ja) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112451T1 (el) | Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης | |
| WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| SE0400284D0 (sv) | Novel compounds | |
| DK1934174T3 (da) | Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme | |
| DK2298768T3 (da) | 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidinderivater og beslægtede forbindelser til behandling af cancer | |
| MY148634A (en) | Pyridazinone derivatives | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| TW200744588A (en) | Pharmaceutical composition for external use | |
| MA32812B1 (fr) | Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| DE602004026903D1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält | |
| WO2007103762A3 (en) | Compositions and methods of use of electron transport system inhibitors | |
| MX2007004740A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica. | |
| EA201201496A1 (ru) | Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты) | |
| TW200626158A (en) | Naphthaline derivatives | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| WO2006072000A3 (en) | Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto | |
| BRPI0516057A (pt) | derivados de indol como inibidores da ciclase de adenilato solúvel | |
| EA200901085A1 (ru) | Производные циклогексиламида арилкарбоновой кислоты | |
| WO2005100322A8 (en) | Sulphur-linked imidazole compounds for the treament of hiv | |
| WO2006078887A3 (en) | Methylphenidate derivatives and uses of them |